Subscribe to RSS
![](/products/assets/desktop/img/oa-logo.png)
DOI: 10.1055/s-0032-1328627
Health Economic Evaluation of Different Decision Aids for the Individualised Treatment of Patients with Breast Cancer
Gesundheitsökonomische Betrachtung der unterschiedlichen Optionen zur individualisierten Therapieentscheidung der Patientin mit einem MammakarzinomPublication History
received 25 March 2013
revised 25 March 2013
accepted 23 April 2013
Publication Date:
26 June 2013 (online)
![](https://www.thieme-connect.de/media/gebfra/201306/lookinside/thumbnails/10.1055-s-0032-1328627-1.jpg)
Abstract
New molecular and genetic tests are becoming more and more important in research and clinical practice. Using these tests to offer individualised therapy to patients with breast cancer is particularly important in the context of health economics. The targeted use of therapies increases their effectiveness and reduces follow-up costs by preventing recurrence and metastatic disease. Avoiding over-treatment additionally reduces costs. Genetic tests are initially associated with higher costs but in the longer term they can reduce costs, as shown by health economic models and cost-effectiveness analyses.
Zusammenfassung
Die individualisierte Therapie der Patientin mit einem Mammakarzinom durch neue Testverfahren, die derzeit sowohl die Forschung als auch den klinischen Alltag bestimmt, ist für die Gesundheitsökonomie besonders relevant, da sie durch den gezielteren Einsatz die Effektivität erhöht und somit Folgekosten durch die Vermeidung von Rezidiven und metastasierten Verläufen senkt. Zudem können durch die Vermeidung von Übertherapien Kosten reduziert werden. Genetische Tests sind zunächst mit erhöhten Kosten assoziiert. Auf die lange Sicht können jedoch Kosten eingespart werden, was durch gesundheitsökonomische Modelle mit Kosten-Effektivitäts-Analysen nachgewiesen werden kann.
-
References
- 1 Albain KS, Barlow WE, Shak S et al. Breast Cancer Intergroup of North America. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010; 11: 55-65
- 2 Anderson K, Jacobson JS, Heitjan DF et al. Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation. Ann Intern Med 2006; 144: 397-406
- 3 Beckmann MW, Bader W, Bechtold I et al. Finanzierung und finanzielle Probleme von Leistungen und Strukturen im Fachgebiet Gynäkologie und Geburtshilfe im Jahr 2011 – allgemeine Aspekte und geburtshilfliche Versorgung. II. Artikel der Finanzierungskommission der DGGG e. V. – Teil I. Geburtsh Frauenheilk 2011; 71: 497-510
- 4 Beckmann MW, Bader W, Bechtold I et al. Finanzierung und finanzielle Probleme von Leistungen und Strukturen im Fachgebiet Gynäkologie und Geburtshilfe im Jahr 2011 – DRG-System und stationäre Versorgung inklusive Urogynäkologie und benigner wie auch maligner gynäkologischer Operationen. II. Artikel der Finanzierungskommission der DGGG e. V. – Teil II. Geburtsh Frauenheilk 2011; 71: 367-380
- 5 Blohmer JU, Rezai M, Kümmel S et al. Using the 21-gene assay to guide adjuvant chemotherapy decision – making in early-stage breast cancer: a cost-efectiveness evaluation in the German setting. J Med Econ 2013; 16: 30-40
- 6 Bundesministerium für Bildung und Forschung. Bevölkerung in Deutschland nach Alter und Geschlecht (Tabelle 0.14). http://www.datenportal.bmbf.de last access: April 2013
- 7 Carey LA, Perou CM, Livasy CA et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295: 2492-2502
- 8 Deenen MJ, Cats A, Sechterberger MK et al. Safety, pharmacokinetics (PK), and cost-effectiveness of upfront genotyping of DPYD in fluoropyrimidine therapy. J Clin Oncol 2011; 29 (Suppl.) Abstr. 3606
- 9 Eiermann W, Rezai M, Kümmel S et al. The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use. Ann Oncol 2013; 24: 618-624
- 10 Elkin EB. The cost of cancer care: how much do we spend and how can we spend it better? SABCS 2011.
- 11 Eisemann N, Waldmann A, Katalinic A. Epidemiology of breast cancer – current figures and trends. Geburtsh Frauenheilk 2013; 73: 130-135
- 12 Hall PS, McCabe C, Stein RC et al. Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer. J Natl Cancer Inst 2012; 104: 56-66
- 13 Hon H, Qiu X, Tobros K et al. Cancer patient acceptance, understanding, and willingness to pay for pharmacogenetic testing (PGT). J Clin Oncol 2012; 30 (Suppl.) Abstr. 6005
- 14 Jacobs VR, Augustin D, Wischnik A et al. Analysis of test-therapy concordance for biomarkers uPA and PAI-1 in primary breast cancer in clinical hospital routine: results of a prospective multi-center study at certified breast cancers in Germany. Cancer Res 2012; 72 (24 Suppl.) 455s-456s
- 15 Kreienberg R, Albert U-S, Follmann M et al. Leitlinienprogramm Onkologie der AWMF, Deutschen Krebsgesellschaft e. V. und Deutschen Krebshilfe e. V. Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms. Langversion 3.0. 2012: 105
- 16 Lee JA, Shaheen M, Walke T et al. Clinical and health economic outcomes of alternative HER2 test strategies for guiding adjuvant trastuzumab therapy. Expert Rev Pharmacoecon Outcomes Res 2011; 11: 325-341
- 17 Loi S, Sotiriou C, Haibe-Kains B et al. Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancer. BMC Med Genomics 2009; 2: 37
- 18 Lüftner D, Lux MP, Maass N et al. Advances in breast cancer – looking back over the year. Geburtsh Frauenheilk 2012; 72: 1117-1129
- 19 Lux MP, Fasching PA, Löhberg CR et al. Health services research and health economy – quality care training in gynaecology, with focus on gynaecological oncology. Geburtsh Frauenheilk 2012; 71: 1046-1055
- 20 Lux MP, Reichelt C, Wallwiener D et al. Results of the Zometa cost-utility model for the German healthcare system based on the results of the ABCSG-12 study. Onkologie 2010; 33: 360-368
- 21 Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817-2826
- 22 Ravdin PM, Siminoff LA, Davis GJ et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001; 19: 980-991
- 23 Reed SD, Dinan MA, Schulman KA et al. Cost-effectiveness of the 21-gene recurrence score assay in the setting of multifactorial decision making for chemotherapy in early-stage breast cancer. J Clin Oncol 2012; 30 (Suppl.) Abstr. 1525
- 24 Retèl VP, Joore MA, Knauer M et al. Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer. Eur J Cancer 2010; 46: 1382-1391
- 25 Robert Koch-Institut, Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V., Hrsg. Krebs in Deutschland 2007/2008. 8. Ausgabe. Berlin: 2012
- 26 Scharl A, Thomssen C, Harbeck N. on behalf of the AGO Breast Committee. AGO recommendations for diagnosis and treatment of patients with early and metastastic breast cancer: Update 2012. BreastCare 2012; 7: 322-335
- 27 Sørlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001; 98: 10869-10874
- 28 Thiel FC, Schrauder MG, Fasching PA et al. Shared decision-making in breast cancer: discrepancy between the treatment efficacy required by patients and by physicians. Breast Cancer Res Treat 2012; 135: 811-820
- 29 Wishart GC, Azzato EM, Greenberg DC et al. PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer. Breast Cancer Res 2010; 12: R1
- 30 Wishart GC, Bajdik CD, Azzato EM et al. A population-based validation of the prognostic model PREDICT for early breast cancer. Eur J Surg Oncol 2011; 37: 411-417
- 31 Wishart GC, Bajdik CD, Dicks E et al. PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2. Br J Cancer 2012; 107: 800-807
- 32 Yang M, Rajan S, Issa AM. Cost effectiveness of gene expression profiling for early stage breast cancer: a decision-analytic model. Cancer 2012; 118: 5163-5170
- 33 Schmidt M, Fasching PA, Beckmann MW et al. Biomarkers in breast cancer – an update. Geburtsh Frauenheilk 2012; 72: 819-832